Author:
Sessa Cristiana,Viganò Lucia,Grasselli Giacomo,Trigo Josè,Marimon Irene,Lladò Anna,Locatelli Alberta,Ielmini Nicoletta,Marsoni Silvia,Gianni Luca
Reference21 articles.
1. SU6668 is a potent antiangiogenic and antitumour agent that induces regression of established tumours;Laird;Cancer Res,2000
2. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumour vasculature and tumour regression in mice;Laird;FASEB J,2002
3. Sugen, SU006668 Investigator Brochure;2002.
4. A phase I study of SU6668 in patients with refractory solid tumours;Brahmer;Proc Am Soc Clin Oncol,2002
5. Phase I dose-escalating trial of oral SU006668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies;Rosen;Proc Am Soc Clin Oncol,2000
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献